Cell. Volume 181, Issue 1, P24-28, April 02, 2020
David Nutt, David Erritzoe, and Robin Carhart-Harris
Centre for Psychedelic Research, Department of Psychiatry, Imperial College London, London W12 0NN, UK
Abstract
After a legally mandated, decades-long global arrest of research on psychedelic drugs, investigation of psychedelics in the context of psychiatric disorders is yielding exciting results. Outcomes of neuroscience and clinical research into 5-Hydroxytryptamine 2A (5-HT2A) receptor agonists, such as psilocybin, show promise for addressing a range of serious disorders, including depression and addiction.
